Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-007 + tislelizumab with bevacizumab + fluoropyrimidine vs bevacizumab + fluoropyrimidine as maintenance in unresectable/metastatic MSS/pMMR colorectal cancer
CTR20223077Phase 2Terminated
- Sponsor
- BeiGene
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alcestobart in colorectal adenocarcinoma, sponsored by BeiGene. Started Dec 2022; status: terminated.
02
Drugs
alcestobart
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20223077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223077.